HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Zhejiang Shimai Pharmaceutical / Equity Capital Markets

<ul>
<li>TCE shows strong potential in hematological malignancies, but once it occurs in solid tumors,it is prone to "cytokine storm".It’s not an easy task to capture a share in this market.</li>
<li>To save cash, Shimai has significantly reduced R&amp;D investment, which would delay or even endanger the advancement of key clinical trials, making it difficult to quickly build solid commercialization system.</li>
<li>Compared with <a href="https://www.smartkarma.com/entities/nanjing-leads-biolabs-co-ltd" target="_blank" data-smartkarma-citation="entities:44126:1" rel="noopener">Leads Biolabs,</a> Shimai is at a clear disadvantage in terms of capital, team size, number of candidates in late clinical stages. Valuation would be lower than Leads Biolabs.</li>
</ul>


TCE shows strong potential in hematological malignancies, but once it occurs in solid tumors,it is prone to "cytokine storm".It’s not an easy task to capture a share in this market.
To save cash, Shimai has significantly reduced R&amp;D investment, which would delay or even endanger the advancement of key clinical trials, making it difficult to quickly build solid commercialization system.
Compared with Leads Biolabs, Shimai is at a clear disadvantage in terms of capital, team size, number of candidates in late clinical stages. Valuation would be lower than Leads Biolabs.


Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zhejiang Shimai Pharmaceutical (ZSM HK)

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

TCE faces challenges in solid tumors due to cytokine storm, Shimai's reduced R&D investment may hinder clinical trials and commercialization,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

​TCE faces challenges in solid tumors due to cytokine storm, Shimai's reduced R&D investment may hinder clinical trials and commercialization,...

Xinyao (Criss) Wang

TCE faces challenges in solid tumors due to cytokine storm, Shimai's reduced R&D investment may hinder clinical trials and commercialization,...